Does Buspirone Cause Nightmares?
Buspirone can cause nightmares and dream disturbances, though this is classified as a "frequent" adverse effect occurring in at least 1 in 100 patients rather than a common side effect. 1
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for Buspar explicitly lists "dream disturbances" as a frequent adverse event in the Central Nervous System category 1. This classification means it occurs in at least 1/100 patients who take the medication. The drug label documents this finding from systematic safety data collected across approximately 3,000 patients who received multiple doses of buspirone during premarketing evaluation 1.
Clinical Context and Mechanism
While buspirone does cause dream disturbances including nightmares, it's important to understand the broader context:
- Buspirone is NOT sedating - Multiple studies confirm it lacks sedative properties and may actually have mild stimulant effects 2, 3, 4
- The drug can increase sleep latency and decrease total sleep time, particularly during initial administration 2
- One study found wake time after sleep onset increased moderately during the first 3 nights of administration, with a marked increase on the first night 2
Comparison to Other Medications
The American Academy of Sleep Medicine guidelines note that drugs affecting neurotransmitters like norepinephrine, serotonin, and dopamine can produce nightmares 5. Buspirone's complex mechanism involves 5-HT1A receptor agonism and dopamine receptor interactions, which may explain its potential to cause dream disturbances 6, 7.
Interestingly, buspirone has been studied as a treatment for PTSD-related sleep problems, with some evidence suggesting it may improve sleep in certain patients 8, though this appears contradictory to its documented dream disturbance effects.
Clinical Recommendations
If a patient develops nightmares on buspirone:
- Consider this a documented adverse effect rather than an idiosyncratic reaction
- The effect may be dose-related and could improve with dose reduction
- Dream disturbances were frequent enough to contribute to the 10% discontinuation rate in premarketing trials 1
- Alternative anxiolytics should be considered if nightmares significantly impact quality of life
Important Caveats
- The frequency of "dream disturbances" in the FDA data does not distinguish between nightmares specifically versus other sleep-related dream phenomena
- Most controlled trials did not systematically assess nightmare frequency as a primary outcome
- The effect may be more pronounced in patients with pre-existing sleep disorders or anxiety conditions